Lawmakers Parrot Drug Makers’ Arguments For Wider CAR-T Coverage

May 08, 2019
As the May 17 final coverage decision looms, bipartisan groups of Senate and House lawmakers are taking the side of drug makers that want Medicare to cover expensive CAR-T cancer therapies for more patients and in more settings. The lawmakers ask that CMS let doctors administer chimeric antigen receptor (CAR) T-cells therapy outside of hospitals, pay for off-label indications, avoid disrupting care of patients already receiving CAR-T and avoid excluding coverage of future cell and gene therapy therapies. CMS is...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.